Galderma Group AG (SWX:GALD)
175.75
-4.90 (-2.71%)
Jul 31, 2026, 5:30 PM CET
Galderma Group AG Revenue
In the year 2025, Galderma Group AG had annual revenue of $5.24B USD with 18.04% growth. Galderma Group AG had revenue of $2.78B in the half year ending December 31, 2025, with 32.02% growth.
Revenue
$5.24B
Revenue Growth
+18.04%
P/S Ratio
9.92
Revenue / Employee
$682.78K
Employees
7,676
Market Cap
41.23B CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.24B | 801.00M | 18.04% |
| Dec 31, 2024 | 4.44B | 323.00M | 7.85% |
| Dec 31, 2023 | 4.12B | 293.10M | 7.66% |
| Dec 31, 2022 | 3.82B | 378.90M | 11.00% |
| Dec 31, 2021 | 3.45B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Sandoz Group AG | 8.85B |
| Alcon | 8.53B |
| Lonza Group AG | 6.87B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.61B |
Galderma Group AG News
- 10 days ago - Galderma Group AG Earnings Call Transcript: Q2 2026 - Transcripts
- 10 days ago - Galderma Group AG Earnings release: Q2 2026 - Filings
- 10 days ago - Galderma Group AG Quarterly report: Q2 2026 - Filings
- 10 days ago - Galderma Group AG Slides: Q2 2026 - Filings
- 10 days ago - Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says - CNBC
- 10 days ago - Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year - Business Wire
- 13 days ago - Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region - Business Wire
- 4 weeks ago - Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States - Business Wire